For the Inventor, By the Inventor

Enter assignee name

Mechelen, Belgium

Galapagos Nv

USPTO Granted Patents = 116

CIPO Patents = 7

EPO Patents = 67

Trademarks = 15

Forward Citations = 376

Loading Chart...

Loading Chart...

188 inventors (with patents filed for the assignee):

Christel Jeanne Marie Menet (28 out of 29 patents)

Nicolas Desroy (23 out of 24 patents)

Steven Emiel Van Der Plas (23 out of 23 patents)

4. Philip R Kym (19 out of 59 patents)

5. Xueqing Wang (19 out of 41 patents)

6. Luke Jonathan Alvey (18 out of 19 patents)

7. Reginald Christophe Xavier Brys (18 out of 20 patents)

8. Christophe Peixoto (17 out of 19 patents)

9. Gregory A Gfesser (15 out of 37 patents)

10. Robert J Altenbach (14 out of 46 patents)

11. Andrew Bogdan (13 out of 19 patents)

12. Xavier Marie Bock (12 out of 12 patents)

13. Christopher Gaëtan Housseman (12 out of 12 patents)

14. Bo Liu (12 out of 28 patents)

15. Oscar Mammoliti (12 out of 12 patents)

Core Competencies:

Inflammatory Disorders

Cystic Fibrosis

ADAMTS Inhibitors

IL-17C Antibodies

JAK Inhibitors

Osteoarthritis Treatments

Polycystic Kidney Disease

Cardiovascular Disorders

Prodrug Modulators

Pharmaceutical Compositions

Transmembrane Conductance Regulator

Heteroaryl Substituted Pyridines

116 patents: Sort by Forward Citations

1. 12472181 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2025-11-18),

2. 12383544 - Methods for the treatment of polycystic kidney disease (2025-08-12),

3. 12264156 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2025-04-01),

4. 12065443 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2024-08-20),

5. 11987621 - Antibodies for IL-17C (2024-05-21),

6. 11975008 - Pharmaceutical compositions comprising a JAK inhibitor (2024-05-07),

7. 11718588 - 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis (2023-08-08),

8. 11667633 - Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2023-06-06),

9. 11564923 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2023-01-31),

10. 11345691 - Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use (2022-05-31),

11. 11339166 - Compounds and pharmaceutical compositions thereof for the treatment of diseases (2022-05-24),

12. 11220499 - Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2022-01-11),

13. 11136325 - Pyrrolopyrimidine and pyrrolopyridine derivatives (2021-10-05),

14. 11072611 - Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2021-07-27),

15. 11000528 - Compound useful for the treatment of degenerative and inflammatory diseases (2021-05-11),

Galapagos NV is a biotechnology company specializing in the discovery and development of small molecule medicines. With a focus on innovative targets, Galapagos aims to develop novel therapies to address unmet medical needs. The company operates globally and collaborates with biopharmaceutical partners to advance promising drug candidates through the development pipeline.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

116 Patents

#1 in Mechelen

#44 in Belgium

#6,645 in the World

Mechelen, Belgium

Galapagos Nv

Forward Citations = 376

188 inventors:

Christel Jeanne Marie Menet (28 out of 29 patents)

Nicolas Desroy (23 out of 24 patents)

Steven Emiel Van Der Plas (23 out of 23 patents)

4. Philip R Kym (19 out of 59 patents)

5. Xueqing Wang (19 out of 41 patents)

Please report any incorrect information to support@idiyas.com

Loading…